Journal
PHARMACOGENOMICS JOURNAL
Volume 11, Issue 3, Pages 207-213Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/tpj.2010.23
Keywords
tetrahydrobiopterin; pharmacogenetics; neurotransmitters; SSRIs
Categories
Funding
- Health Research Council of New Zealand, Canterbury Medical Research Foundation
Ask authors/readers for more resources
Tetrahydrobiopterin (BH4) is an essential cofactor for synthesis of many neurotransmitters including serotonin. In serotonergic neurons, BH4 is tightly regulated by GTP-cyclohydrolase I feedback regulator (GFRP). Given the pivotal role of the serotonergic system in mood disorders and selective serotonin reuptake inhibitors (SSRIs) antidepressant function, we tested the hypothesis that GFRP gene (GCHFR) variants would modify response to antidepressants in subjects with major depression. Two single nucleotide polymorphisms (rs7164342 and rs7163862) in the GCHFR promoter were identified and occurred as two haplotypes (GA or TT). A multiple regression analysis revealed that homozygous individuals for the TT haplotype were less likely to respond to the SSRI fluoxetine than to the tricyclic antidepressant nortriptyline (P=0.037). Moreover, the TT haplotype showed a reduced transcription rate in luciferase reporter gene assays, which may impact on BH4-mediated neurotransmitter production, thus suggesting a biological process through which GCHFR promoter variants might influence antidepressant response. The Pharmacogenomics Journal (2011) 11, 207-213; doi:10.1038/tpj.2010.23; published online 30 March 2010
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available